Ketoprofen vs. Diclofenac Topical: Pain Relief for PI Patients
Amar Lunagaria — Chief Pharmacist, LienScripts | March 29, 2026 | 7 min read
Ketoprofen and diclofenac are the two most studied topical NSAIDs for musculoskeletal pain. This comparison covers clinical evidence, availability, insurance coverage, and when each is preferred for personal injury patients.
Ketoprofen and diclofenac are the two topical NSAIDs with the strongest clinical evidence for localized musculoskeletal pain, and choosing between them in a personal injury case depends on the injury type, the patient's access situation, and whether the clinical benefit of compounded ketoprofen justifies the additional access complexity compared to commercially available diclofenac (Voltaren Gel, Pennsaid). Both are effective topical analgesics that minimize the systemic risks of oral NSAIDs, but they differ in important ways that affect PI patient treatment and settlement documentation.
- Ketoprofen topical demonstrated a number needed to treat (NNT) of 2.6 for acute musculoskeletal pain versus diclofenac topical's NNT of 4.7 in a Cochrane systematic review, suggesting superior efficacy for ketoprofen (Derry et al., Cochrane Database of Systematic Reviews, 2015)
- Diclofenac topical is commercially available in the U.S. (Voltaren Gel 1%, Pennsaid 1.5% and 2% solutions) while ketoprofen topical requires compounding pharmacy preparation, creating fundamentally different access pathways
- LienScripts dispenses both medications on pharmacy lien — commercial diclofenac and compounded ketoprofen — and documents each in the POGOS (Pharmacy-Organized General Occurrence Summary) report with clinical context for the prescriber's choice
- According to James Wong, PharmD, founder of LienScripts, "Diclofenac topical is the accessible option; ketoprofen topical is the more effective option. When a physician prescribes compounded ketoprofen over commercially available diclofenac, it documents a clinical judgment that the patient's condition requires the stronger agent"
- The FDA approved diclofenac topical gel (Voltaren) in 2007 for osteoarthritis of joints amenable to topical treatment, and approved OTC Voltaren Arthritis Pain in 2020; no topical ketoprofen product has received FDA approval in the U.S. market
Head-to-Head Efficacy Comparison
Cochrane Review Evidence
The most comprehensive comparison comes from the Cochrane Collaboration's systematic reviews of topical NSAIDs. Key findings:
| Metric | Ketoprofen Topical | Diclofenac Topical |
|---|---|---|
| NNT (acute pain) | 2.6 | 4.7 |
| Success rate vs. placebo | Significantly superior | Significantly superior |
| Onset of action | 1-2 hours | 1-2 hours |
| Duration of effect | 8-12 hours | 6-8 hours |
| Evidence quality | High (multiple RCTs) | High (multiple RCTs) |
The lower NNT for ketoprofen means that fewer patients need to be treated for one patient to achieve clinically meaningful pain relief — a standard measure of drug effectiveness.
Mechanism Differences
Both drugs inhibit cyclooxygenase (COX) enzymes to reduce local prostaglandin production and inflammation. However:
Ketoprofen — More potent COX inhibitor per milligram. Better skin penetration due to optimal molecular weight and lipophilicity. May have additional analgesic effects through bradykinin antagonism.
Diclofenac — Slightly larger molecular weight with slower tissue penetration. Well-characterized pharmacokinetics from decades of commercial use. Additional activity at vanilloid receptors (TRPV1) that may contribute to analgesic effects.
[!KEY] The clinical evidence slightly favors ketoprofen topical for efficacy, but diclofenac topical has a major practical advantage: it is commercially available and FDA-approved in the United States. The choice between them is a clinical decision that depends on the patient's specific condition, access situation, and the treating physician's judgment.
When Physicians Choose Ketoprofen Over Diclofenac
Pain management specialists and orthopedists prescribe compounded ketoprofen topical when:
Diclofenac has been tried and provides insufficient relief. Step therapy from commercial diclofenac to compounded ketoprofen is a common progression that documents treatment escalation in the pharmacy record.
The injury involves deep tissue structures. Ketoprofen's superior skin penetration may provide better drug delivery to deeper structures — tendons, joint capsules, and bursae.
Multi-agent compounding is needed. When the physician wants ketoprofen combined with other topical agents (lidocaine for numbing, gabapentin for neuropathic pain, cyclobenzaprine for muscle spasm) in a single application, the compound must be prepared by a compounding pharmacy regardless — and ketoprofen becomes the logical NSAID component given its superior topical evidence.
The patient needs higher concentrations. Commercial diclofenac is available at 1-2% concentration. Compounded ketoprofen can be prepared at 10-20% concentration — a 5-10x higher concentration that delivers substantially more drug to the target tissue.
[!TIP] When reviewing pharmacy records, the progression from commercial diclofenac to compounded ketoprofen documents treatment escalation — the commercially available product was insufficient, and the physician escalated to a compounded medication with stronger evidence. This progression supports the argument that the patient's pain condition is more severe than what standard commercial medications can address.
Access and Insurance Comparison
Diclofenac Topical
- Commercial availability: Widely available at all pharmacies
- OTC option: Voltaren Arthritis Pain is available over the counter (1% gel)
- Prescription options: Voltaren Gel 1% (Rx), Pennsaid 1.5% and 2% solution (Rx)
- Insurance coverage: Generally covered with standard copays; prior authorization uncommon
- Documentation value: Moderate — commercially available, OTC version exists
Ketoprofen Topical
- Commercial availability: Not available as a manufactured product in the U.S.
- Compounding required: Must be prepared by a compounding pharmacy
- Prescription only: No OTC option exists
- Insurance coverage: Rarely covered due to compounding exclusions and lack of NDC
- Documentation value: Higher — requires specialty preparation, documents need beyond commercial products
As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, "From a documentation perspective, compounded ketoprofen topical carries more weight in a demand package than commercial diclofenac because it demonstrates that the patient's condition required a medication that could not be obtained at a regular pharmacy. The pharmacy lien makes this accessible, and the POGOS report explains the clinical rationale."
PI-Specific Prescribing Considerations
Acute Injuries (First 2-4 Weeks)
For acute soft tissue injuries, either topical NSAID is appropriate. Diclofenac is often the initial choice due to immediate availability. The Cochrane data favoring ketoprofen is particularly strong for acute musculoskeletal pain.
Chronic/Persistent Injuries (4+ Weeks)
For injuries that persist beyond the acute phase, the higher potency and deeper tissue penetration of compounded ketoprofen may provide clinical advantages. The escalation from diclofenac to ketoprofen documents chronicity.
Post-Surgical Pain
Topical NSAIDs at the surgical site can supplement systemic pain management while avoiding additional oral NSAID burden. Compounded ketoprofen at higher concentrations (15-20%) may be preferred for deeper surgical sites.
Patients on Oral NSAIDs
Some PI patients require both oral and topical NSAID therapy. Topical ketoprofen's minimal systemic absorption (1-5% of oral bioavailability) makes it safer to combine with oral NSAIDs than adding a second oral agent.
[!KEY] Both ketoprofen and diclofenac topical are legitimate, evidence-based treatments for PI patients. The pharmacy lien ensures access to whichever the physician prescribes — including compounded ketoprofen that insurance would otherwise deny. The POGOS report documents the clinical rationale for the specific agent chosen.
FAQs
Related Resources
- Ketoprofen Topical for Pain After an Injury
- Diclofenac for Joint Pain After a Fall
- Compound Medication Customization on Pharmacy Lien
- What Is a Pharmacy Lien?
Frequently Asked Questions
Is ketoprofen topical more effective than diclofenac topical?
Cochrane systematic review data shows ketoprofen topical has a lower NNT (2.6 vs. 4.7) than diclofenac for acute musculoskeletal pain, suggesting superior efficacy. However, diclofenac is commercially available in the U.S. while ketoprofen requires compounding. The treating physician determines which is appropriate based on the patient's specific clinical situation.
Why would a doctor prescribe compounded ketoprofen instead of Voltaren?
Physicians prescribe compounded ketoprofen when diclofenac provides insufficient relief, when higher concentrations are needed for deeper tissue injuries, or when a multi-agent compound (ketoprofen + lidocaine + other agents) is clinically appropriate. The escalation from diclofenac to ketoprofen documents treatment progression in the pharmacy record.
Does insurance cover ketoprofen topical?
Insurance rarely covers compounded ketoprofen topical due to the lack of a commercial product, compounding exclusions, and NDC requirements. Commercial diclofenac products (Voltaren, Pennsaid) are generally covered. A pharmacy lien covers both medications at no upfront cost to the PI patient.
Can I use both ketoprofen and diclofenac topical together?
Using two topical NSAIDs simultaneously is not recommended as it increases local skin irritation risk without proven additive benefit. Typically, the physician selects one topical NSAID based on clinical response. Switching from diclofenac to ketoprofen — rather than combining them — is the standard escalation pattern.